Catalog No.S1197 Synonyms: MK-906
Molecular Weight(MW): 372.54
Finasteride is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).
Purity & Quality Control
Choose Selective 5-alpha Reductase Inhibitors
|Description||Finasteride is a potent, reversible inhibitor of the rat type 1 5 alpha-reductase with Ki of 10.2 nM, used in the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).|
Finasteride binds to the type 2 isozyme-NADPH complex to form a ternary complex with Ki of 1.19 nM, which then rearranges to a high affinity complex (E:I) with a pseudo first order rate constant of 1.62 ms.  Finasteride dose-dependently inhibits the growth rate of the LnCap cell line.  Finasteride markedly inhibits prostate-specific antigen (PSA) secretion and expression in LNCaP cells. 
|In vivo||Finasteride induces dosage-related incidences of hypospadias (penischisis) in male offspring with a threshold dosage level near 0.1 mg/kg/day and a 100% effect level of 100 mg/kg/day in male rats. Finasteride also causes decreased anogenital distance in male offspring in male rats.  Finasteride and castration decreases prostate weight at day 21 by 65% and 93%, respectively, in rats. Finasteride has no significant effect on DNA content after 4 days and decreases DNA content by a maximum of 52% at 14 days in rats. Finasteride causes a less intense increase in staining in which 16% of epithelial cells stained for tissue transglutaminase on day 9 with a return to baseline by day 14 in rats. Finasteride-induced staining is less intense with peak staining at day 4 (0.7% of epithelial cells) and a return to control values by day 9 in rats. |
-  Azzolina B, et al. J Steroid Biochem Mol Biol, 1997, 61(1-2), 55-64.
-  Bologna M, et al. Urology, 1995, 45(2), 282-290.
-  Wang LG, et al. Cancer Res, 1997, 57(4), 714-719.
|In vitro||DMSO||75 mg/mL (201.32 mM)|
|Ethanol||75 mg/mL (201.32 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03669692||Recruiting||Behavioral: Caloric Restriction|Behavioral: Control||Prostatic Hyperplasia Benign|Metabolic Syndrome||Complexo Hospitalario Universitario de A Coruña||July 10 2018||Not Applicable|
|NCT02824380||Completed||Drug: DA-4001 H|Drug: DA-4001 L||Androgenic Alopecia||Dong-A ST Co. Ltd.||July 2016||Phase 1|
|NCT02146937||Withdrawn||Drug: Bicalutamide plus Finasteride- Combination therapy||Detectable Prostate Nodules||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||March 2014||Phase 2|
|NCT01703520||Completed||--||Male Breast Cancer||Merck Sharp & Dohme Corp.|Institute for Applied Economics and Health Research Aps||May 1 2011||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.